Does the media favor AXSM or IDYA?

In the previous week, Axsome Therapeutics had 10 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Axsome Therapeutics and 4 mentions for IDEAYA Biosciences. Axsome Therapeutics' average media sentiment score of 0.61 beat IDEAYA Biosciences' score of 0.48 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IDYA or SMMT more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Summit Therapeutics N/A -291.24% -243.07%

Does the media prefer IDYA or SMMT?

In the previous week, Summit Therapeutics had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 5 mentions for Summit Therapeutics and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.48 beat Summit Therapeutics' score of 0.42 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ELAN or IDYA?

In the previous week, Elanco Animal Health had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Elanco Animal Health and 4 mentions for IDEAYA Biosciences. Elanco Animal Health's average media sentiment score of 1.31 beat IDEAYA Biosciences' score of 0.48 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARWR or IDYA?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 4 mentions for IDEAYA Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat IDEAYA Biosciences' score of 0.48 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RDY or IDYA?

IDEAYA Biosciences has a consensus target price of $50.25, indicating a potential upside of 39.54%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 IDEAYA Biosciences 1 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.82

Does the media refer more to RDY or IDYA?

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 4 articles in the media. IDEAYA Biosciences' average media sentiment score of 0.48 beat Dr. Reddy's Laboratories' score of 0.42 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

IDEAYA Biosciences (IDYA) Competitors

$36.01 +0.08 (+0.22%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$36.75 +0.74 (+2.05%)

As of 07/17/2026 04:45 PM Eastern

Compare

IDYA vs. AXSM, SMMT, ELAN, ARWR, and RDY

Should you buy IDEAYA Biosciences stock or one of its competitors? MarketBeat compares IDEAYA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEAYA Biosciences include Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does IDEAYA Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

IDEAYA Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. IDEAYA Biosciences' return on equity of -14.24% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Axsome Therapeutics presently has a consensus target price of $259.05, indicating a potential upside of 12.63%. IDEAYA Biosciences has a consensus target price of $50.25, indicating a potential upside of 39.54%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

IDEAYA Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.54	-$183.17M	-$3.73	N/A
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A

In the previous week, Axsome Therapeutics had 10 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 14 mentions for Axsome Therapeutics and 4 mentions for IDEAYA Biosciences. Axsome Therapeutics' average media sentiment score of 0.61 beat IDEAYA Biosciences' score of 0.48 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Axsome Therapeutics beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Summit Therapeutics?

IDEAYA Biosciences (NASDAQ:IDYA) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

IDEAYA Biosciences has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

In the previous week, Summit Therapeutics had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 5 mentions for Summit Therapeutics and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.48 beat Summit Therapeutics' score of 0.42 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has higher revenue and earnings than Summit Therapeutics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

IDEAYA Biosciences presently has a consensus target price of $50.25, suggesting a potential upside of 39.54%. Summit Therapeutics has a consensus target price of $26.97, suggesting a potential upside of 95.31%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

IDEAYA Biosciences' return on equity of -14.24% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Summit Therapeutics	N/A	-291.24%	-243.07%

Summary

IDEAYA Biosciences beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Elanco Animal Health currently has a consensus target price of $28.55, suggesting a potential upside of 10.47%. IDEAYA Biosciences has a consensus target price of $50.25, suggesting a potential upside of 39.54%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

IDEAYA Biosciences has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

IDEAYA Biosciences has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.64	-$232M	-$0.50	N/A
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A

In the previous week, Elanco Animal Health had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Elanco Animal Health and 4 mentions for IDEAYA Biosciences. Elanco Animal Health's average media sentiment score of 1.31 beat IDEAYA Biosciences' score of 0.48 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

IDEAYA Biosciences beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Arrowhead Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$622.01M	16.83	-$1.63M	-$2.15	N/A
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 4 mentions for IDEAYA Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat IDEAYA Biosciences' score of 0.48 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals presently has a consensus price target of $88.75, suggesting a potential upside of 19.45%. IDEAYA Biosciences has a consensus price target of $50.25, suggesting a potential upside of 39.54%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Arrowhead Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IDEAYA Biosciences has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. IDEAYA Biosciences' return on equity of -14.24% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Summary

IDEAYA Biosciences beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to IDEAYA Biosciences' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Dr. Reddy's Laboratories has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$335.93B	0.03	$456M	$0.58	21.78
IDEAYA Biosciences	$218.71M	14.47	-$113.70M	-$1.60	N/A

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 4 articles in the media. IDEAYA Biosciences' average media sentiment score of 0.48 beat Dr. Reddy's Laboratories' score of 0.42 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a consensus target price of $50.25, indicating a potential upside of 39.54%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats IDEAYA Biosciences on 8 of the 15 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.16B	$3.69B	$6.86B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-22.51	21.03	27.21	23.92
Price / Sales	14.47	177.07	517.68	88.89
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	3.09	8.26	10.69	6.18
Net Income	-$113.70M	$23.83M	$3.59B	$332.29M
7 Day Performance	-2.65%	-3.47%	-2.20%	-2.05%
1 Month Performance	15.31%	2.69%	1.63%	-2.18%
1 Year Performance	66.79%	45.93%	25.64%	17.67%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.3017 of 5 stars	$36.01 +0.2%	$50.25 +39.5%	+66.8%	$3.16B	$218.71M	N/A	80	News Coverage Gap Down
AXSM Axsome Therapeutics	3.6375 of 5 stars	$245.57 -1.7%	$259.05 +5.5%	+105.9%	$12.85B	$638.50M	N/A	380	News Coverage Analyst Forecast
SMMT Summit Therapeutics	3.2677 of 5 stars	$15.69 -1.2%	$26.97 +71.9%	-47.3%	$12.33B	N/A	N/A	110	News Coverage Upcoming Earnings Analyst Forecast Gap Down
ELAN Elanco Animal Health	3.7359 of 5 stars	$24.70 +0.2%	$28.55 +15.6%	+74.8%	$12.31B	$4.72B	N/A	9,400	News Coverage Positive News
ARWR Arrowhead Pharmaceuticals	3.1152 of 5 stars	$85.74 -1.4%	$87.27 +1.8%	+343.3%	$12.25B	$829.45M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. AXSM, SMMT, ELAN, ARWR, and RDY

How does IDEAYA Biosciences compare to Axsome Therapeutics?

Summary

How does IDEAYA Biosciences compare to Summit Therapeutics?

Summary

How does IDEAYA Biosciences compare to Elanco Animal Health?

Summary

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. AXSM, SMMT, ELAN, ARWR, and RDY

How does IDEAYA Biosciences compare to Axsome Therapeutics?

Is AXSM or IDYA more profitable?

Do analysts rate AXSM or IDYA?

Do insiders and institutionals have more ownership in AXSM or IDYA?

Which has more volatility & risk, AXSM or IDYA?

Which has higher earnings and valuation, AXSM or IDYA?

Does the media favor AXSM or IDYA?

Summary

How does IDEAYA Biosciences compare to Summit Therapeutics?

Which has more volatility and risk, IDYA or SMMT?

Does the media prefer IDYA or SMMT?

Which has higher earnings and valuation, IDYA or SMMT?

Do analysts recommend IDYA or SMMT?

Do insiders and institutionals believe in IDYA or SMMT?

Is IDYA or SMMT more profitable?

Summary

How does IDEAYA Biosciences compare to Elanco Animal Health?

Do analysts prefer ELAN or IDYA?

Is ELAN or IDYA more profitable?

Which has more volatility and risk, ELAN or IDYA?

Which has stronger earnings & valuation, ELAN or IDYA?

Does the media refer more to ELAN or IDYA?

Do institutionals & insiders hold more shares of ELAN or IDYA?

Summary

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Which has preferable valuation & earnings, ARWR or IDYA?

Does the media favor ARWR or IDYA?

Do analysts prefer ARWR or IDYA?

Which has more volatility & risk, ARWR or IDYA?

Do institutionals and insiders hold more shares of ARWR or IDYA?

Is ARWR or IDYA more profitable?

Summary

How does IDEAYA Biosciences compare to Dr. Reddy's Laboratories?

Do institutionals & insiders have more ownership in RDY or IDYA?

Is RDY or IDYA more profitable?

Which has higher valuation and earnings, RDY or IDYA?

Does the media refer more to RDY or IDYA?

Do analysts recommend RDY or IDYA?

Which has more volatility & risk, RDY or IDYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools